Brian E. Gilbert, Ph.D.
Department of Molecular Virology & Microbiology
Aerosolized Drugs for Pulmonary Diseases
Respiratory viral diseases are important causes of morbidity and mortality. Development and evaluation of new antivirals and vaccines to prevent these respiratory diseases is an important part of my research. Currently, I conduct preclinical studies on potentially new drugs and vaccine candidates for activity against respiratory viruses such as influenza viruses, respiratory syncytial virus (RSV), parainfluenza viruses, measles, adenoviruses and others. While these drugs may be given in a variety of ways, I continued to develop aerosol drug delivery as the best way to directly target the lungs for the treatment of pulmonary infectious diseases. Reformulating drugs in liposomes or nanoparticles and directly targeting the lungs by aerosol administration, I have been able to achieve lung concentrations that are 10- to 100-fold higher than administering these compounds by more conventional routes. This drug delivery system may increase local effectiveness while decreasing systemic toxicity, creating a greater therapeutic window. I have used this approach to treat pulmonary, as well as systemic, disease in both humans, and in animal models of influenza viruses and RSV infections, fungal infections and immune mediated disease.
Baylor College of Medicine
One Baylor Plaza
Houston, TX 77030
Ph.D., University of California, Los Angeles
Postdoctoral, Northwestern University School of Medicine
Englund, J.A., P.A. Piedra, Y M. Ahn, B.E. Gilbert and P. Hiatt. 1994. High dose, short duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J. Pediatr. 125:635 641.
Wyde, P.R., D.K. Moore-Poveda, B. O’Hara, W-D. Ding, B. Mitsner and B.E. Gilbert. 1998. CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Res. 38:31-42.
Wyde, P.R., D.K. Moore-Poveda, E. DeClercq, J. Neyts, A. Matsuda, N. Minakawa, E. Guzman and B.E. Gilbert. 2000. Use of cotton rats to evaluate the efficacy of antivirals in the treatment of measles virus infections. Antimicrob. Agents Chemother. 44:1146-1152.
Wyde, P.R., K.J. Stittelaar, A.D.M.E. Osterhaus, E. Guzman and B.E. Gilbert. 2000. Use of cotton rats for preclinical evaluation of measles virus vaccines. Vaccine 19:42-53.
Wyde, P.R., S. Laquerre, S.N. Chetty, B.E. Gilbert, T. Nitz and D.C. Pevear. 2005. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 68:18-26.
Gilbert, B.E. and M.T. McLeay. 2008. MegaRibavirin aerosol for the treatment of influenza virus infections in mice. Antiviral Res. 78:223-229.
Tuvim, M.J., S.E. Evans, C.G. Clement, B.F. Dickey and B.E. Gilbert. 2009. Augmented lung inflammation protects against influenza A pneumonia. PLoS ONE 4:e4176.
Tai, W., L. Roberts, A. Seryshev, J. M. Gubatan, C. S. Bland, R. Zabriskie, S. Kulkarni, L. Soong, I. Mbawuike, B. Gilbert, F. Kheradmand and D. B. Corry. 2011. Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic. Mucosal Immunology 4:197-207.